Hogan Lovells advises Valneva regarding its purchase agreement with the European Commission for its Inactivated Covid-19 Vaccine Candidate VLA2001

Valneva is a company specialized in the development and commercialization of prophylactic vaccines against infectious diseases with significant unmet medical needs. The company has leveraged its expertise and infrastructure to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates in clinical development, including Lyme disease, Chikungunya virus and COVID-19 vaccine candidates.

The European Commission had approved the APA earlier this month.

Under the APA, Valneva may supply up to 60 million doses of its vaccine, over two years. The company expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the European Medicines Agency (EMA). The EC has the option to increase this initial firm purchase order of vaccine up to a total of 60 million doses, the remainder of which would be delivered in 2023.

Following the signing of this agreement, Valneva will be able to help address the ongoing pandemic as well as optimize its manufacturing strategy for VLA2001.

The Hogan Lovells team was composed by Jean-Marc Franceschi (partner), Mikael Salmela (partner), Maimouna Goudiaby (senior associate) and Daghan Ozturk (associate).